ArticleScientific reports2025
Developing muscarinic receptor M1 classification models utilizing transfer learning and generative AI techniques.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence in Drug Discovery and Development: Raising Quality per Decision.Pharmacopsychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Muscarinic receptor subtype 1 (M1) is a G protein-coupled receptor (GPCR) and a key pharmacological target for peripheral neuropathy, chronic obstructive pulmonary disease, nerve agent exposures, and cognitive disorders. Screening and identifying compounds with potential to interact with M1 will aid in rational drug design for these disorders. In this work, we developed machine learning-based M1 classification models utilizing publicly available bioactivity data. As inactive compounds are rarely reported in the literature, we encountered the problem of imbalanced datasets. We investigated two strategies to overcome this bottleneck: 1) transfer learning and 2) using generative models to oversample the inactive class. Our analysis shows that these approaches reduced misclassification of the inactive class not only for M1 but also for other GPCR targets. Overall, we have developed classification models for M1 receptor that will enable rapid screening of large chemical databases and advance drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.